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IS cxaosed to a 
Ventricular fibrillation (WF) refractory to car~io~ulmon~fy 
atlon and multiple transthoraci 
severe coronary disease with !.V 
recurrent monomorphic ventricular 
obstructive pulmonary disease an 
treated with antiarrhythmic agent 
mexiletine; and procainamide and mexiiefine) at time of study. In 
each. stable monomorphic WT (CLs - 320, 350, and 570 ms) was 
initially induced, and overdrive venlricular paein 
to VF. Multiple transthoracic defibrillations (7 t5/pl, using up to 
500 J) failed to terminate these arrhythmias. As a last resort, 
intracardiac defibrillation was performed using a standard 
defibrillator connected to a 6 Fr RV quadripolar catheter (distal pole 
aoved useful in 
rllib) in the course of cardiac resuscitaflon resistant to multiple high 
energy transthoracic defibrillations. 
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The automatic ~rn~9a~ta~9e cardiovcrtes- 
rked hpact on the o~mxne 
ri9lator (AJCD) 
tcme of patients with 
icular tachycardia (~~)/~~~r~99atioR (VF) 
imp9antation. H’e followed 98 patients with 
rug-refractory VT/W evaluated during March 1983 through 
uly 9990 ~910 were recommended AICD implantation after 
drug failure by serial programned electrical stimulation 
(PES). but who refused surgery. Patient characteristics were: 
males 96, mean age 69 years (M-87), mesn ejection fr,cticn 
disease 95. valvular sease 2, 
atients were disc rged on “best” 
spy as evaluated by PES Yihere 
ifteen patients bad inducible 
hythmic drugs and failed a mean 3 
ents had ~o~j~~~~~b~e V%;VF. Eleven patients 
ged on amiodaro~e, 5 patients on Class 1 drugs, 
a-blocker. 8ne patient died OF rcfractorg heart 
ischarge. Ao mean 94 months (l-35) follouup, 6 
ents discharged were alive, 1 I were dead: $823 7 
ke heart failure 2, 
ut SCD had Pecurrenl 
h resuscitation (2) or 
rrence oi QT;\‘F occurred 
at in patients with drug- 
whom MCD has been recommended but 
rognosis is poor despite “best” drug 
therapy. 
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CHOICE IN HIGH RISK PATI S WITH DILATED CARDIOHYOPATHY 
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Antiarrhythmfc drug therapy as 
automatic defibrillators (MD) 
available to treat patients 
cardfomvopathies (DCH). We 
(Pts) with di 
analyzed the 
we1 
are 
1 as implantable 
modalities of therapy 
.lated 
outcome 
ent efecerophysiology studies (EPS) at 
our center. P included 11 pts tc 
tic defxbrilletors (I 
these 11 presented with sudden death (SCD), sustained VT 
or syncope with inducible sustained mono 
Grout II presented similarly with SCD, austained VT, or 
SvncORe . but were treated with EPS guided drug therapy 
&oun‘III included pts with dizziness or lesser 
symptom, and no documented sustained VT. Drug therapy 
in group III, if any, were also guided by EPS results. 
Clinical variables and follow-up durations were similar 
in all groups. Results are as follows: 
Group I Group II Group III 
sudden death 
Other deaths 
* p<O.Ol vs groups IJ 
Five (45%) of Group I Pts received appropriate shocks 
during follow-up. 
Conclusions: ZAD therapy appears to uperbor to EPS 
guided dn g therapy in preve:lting SC ong DC19 Pts who 
initially present with SCD. sustained VT or syncope. 
